KRAS: From undruggable to approval

Wednesday, June 3, 2026 | 11:00 AM - 1:00 PM ET

For decades, KRAS sat at the top of oncology's most-wanted list — and just as long, it stayed out of reach. The first approved KRAS therapies cracked that open, and the research has accelerated ever since.

Now, new pancreatic cancer data suggests the field could be on the edge of something bigger.

Join Endpoints News and the pioneers driving this work at ASCO as we dive into recent progress, the pancreatic cancer data getting attention, and where KRAS research goes from here. Get your spot now.

SPONSORED BY

Sponsorship opportunities are available.
Contact Meg at mestacio@endpointsnews.com to learn how you can support Endpoints at ASCO 2026.